GU Cancers 2020 | Kidney cancer: MK-64982 & sitravatinib with nivolumab

Daniel Geynisman

Daniel Geynisman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses novel combinations in renal cell cancers, specifically focusing on studies of MK-64982 and sitravatinib with nivolumab. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter